Evidence map›Paper›PMID 38921803›Full record

ArticlePathogens (Basel, Switzerland)2024

The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study.

Giulia Anna Maria Luigia Costanzo, Giuseppina Sanna, Francesco Pes, Carla Maria Deiana, Andrea Giovanni Ledda, Andrea Perra, Vanessa Palmas, Valeria Manca, Michela Miglianti, Ferdinando Coghe and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giulia Anna Maria Luigia CostanzoDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0003-2269-0439
Giuseppina SannaMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.ORCID 0000-0002-3999-4263
Francesco PesDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Carla Maria DeianaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0009-0006-3596-5285
Andrea Giovanni LeddaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Andrea PerraOncology and Molecular Pathology Unit, Department of Biomedical Sciences, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0002-8098-899X
Vanessa PalmasMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.
Valeria MancaMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.
Michela MigliantiDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Ferdinando CogheLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042 Monserrato, Italy.
Aldo ManzinMicrobiology and Virology Unit, Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.ORCID 0000-0003-2961-3428
Stefano Del GiaccoDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
Luchino ChessaDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0002-9474-0995
Davide FirinuDepartment of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0002-5768-391X

Funding

Associazione per l'Avanzamento della Ricerca per i Trapianti O.D.V no numberFondazione di Sardegna 2021 n. F73C22001270007NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases Project n. PE00000007, INF-ACT
6 · The paper itself

Abstract

Immunization against COVID-19 is needed in patients with immune-mediated inflammatory diseases (IMIDs). However, data on long-term immunity kinetics remain scarce. This study aimed to compare the humoral and cellular response to COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) compared to healthy controls. We compared the humoral and cellular response to SARS-Cov-2 elicited by vaccination and/or infection in a prospective cohort of 20 IMID patients compared with a group of 21 healthcare workers (HCWs). We assessed immunity before and after the third and fourth dose of BNT162b2 or after COVID-19 infection using quantitative IgG anti-SARS-CoV-2 Spike antibody (anti-S-IgG), neutralization assay, and specific interferon-gamma (IFN-g) release assay (IGRA). The responses were compared with those of healthy controls. The two groups were similar in age and total exposure, becoming infected for the first time, mainly after the third dose. Neutralizing antibodies and IGRA were negative in 9.5% of IMID patients but not in any HCWs. No significant difference was found between neutralization titers to BA.1 in the IMID and the HCW groups. The study highlights the SARS-CoV-2 immunological responses in healthy controls and IMID patients, suggesting that the combined stimuli of vaccination and infection in IMID patients could promote a more profound immunological response.

Indexed as

Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19Immunity, CellularImmunity, HumoralSARS-CoV-2AdultAgedCOVID-19 VaccinesFemaleHealth PersonnelHumansImmunoglobulin GMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, CoronavirusCOVID–19immune-mediated diseasesinfectionsinterferon-gamma release assayvaccine

Identifiers

PMID38921803
PMCPMC11206661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.